Drug
Evolocumab
Evolocumab: highest development phase Post-Market, developed by Amgen. 4 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Amgen
Trials
| Drug | Phase | Indication |
|---|---|---|
| Evolocumab NCT05284747 | Post-Market | Cardiovascular Disease |
| Evolocumab NCT04608474 | Post-Market | Hyperlipidemias |
| Evolocumab NCT02867813 | Phase 3 | Dyslipidemia |
| Evolocumab NCT01380730 | Phase 2 | Hyperlipidemia |
Latest
No recent events.
Follow Evolocumab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.